413 related articles for article (PubMed ID: 10418587)
1. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients.
Duren M; Siperstein AE; Shen W; Duh QY; Morita E; Clark OH
Surgery; 1999 Jul; 126(1):13-9. PubMed ID: 10418587
[TBL] [Abstract][Full Text] [Related]
2. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation].
Vincze B; Sinkovics I; Keresztes S; Gergye M; Boér A; Remenár E; Péter I; Szentirmay Z; Kremmer T; Kásler M
Magy Onkol; 2004; 48(1):27-34. PubMed ID: 15105893
[TBL] [Abstract][Full Text] [Related]
4. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
5. Patients with differentiated thyroid cancer have a venous gradient in thyroglobulin levels.
Kebebew E; Reiff E
Cancer; 2007 Mar; 109(6):1078-81. PubMed ID: 17279579
[TBL] [Abstract][Full Text] [Related]
6. Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.
Krausz Y; Uziely B; Nesher R; Chisin R; Glaser B
Isr Med Assoc J; 2001 Nov; 3(11):843-9. PubMed ID: 11729583
[TBL] [Abstract][Full Text] [Related]
7. Followup of patients with papillary thyroid cancer: in search of the optimal algorithm.
Mittendorf EA; Wang X; Perrier ND; Francis AM; Edeiken BS; Shapiro SE; Lee JE; Evans DB
J Am Coll Surg; 2007 Aug; 205(2):239-47. PubMed ID: 17660070
[TBL] [Abstract][Full Text] [Related]
8. The additive clinical value of combined thyroglobulin and antithyroglobulin antibody measurements to define persistent and recurrent disease in patients with differentiated thyroid cancer.
Aras G; Gültekin SS; Küçük NO
Nucl Med Commun; 2008 Oct; 29(10):880-4. PubMed ID: 18769305
[TBL] [Abstract][Full Text] [Related]
9. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the diagnostic value of the first thyroglobulin determination in detecting metastases after differentiated thyroid carcinoma surgery.
Makarewicz J; Adamczewski Z; Knapska-Kucharska M; Lewiński A
Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):485-9. PubMed ID: 17115345
[TBL] [Abstract][Full Text] [Related]
11. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 < 1 ng/ml determined by traditional assays?
Rosario PW; Purisch S
Clin Endocrinol (Oxf); 2008 Mar; 68(3):338-42. PubMed ID: 17850379
[TBL] [Abstract][Full Text] [Related]
12. Algorithm for safe and effective reoperative thyroid bed surgery for recurrent/persistent papillary thyroid carcinoma.
Farrag TY; Agrawal N; Sheth S; Bettegowda C; Ewertz M; Kim M; Tufano RP
Head Neck; 2007 Dec; 29(12):1069-74. PubMed ID: 17563908
[TBL] [Abstract][Full Text] [Related]
13. Thyroglobulin monitoring after treatment of well-differentiated thyroid cancer.
Hamy A; Mirallié E; Bennouna J; Resche I; Drefty C; Johnstone M; Visset J
Eur J Surg Oncol; 2004 Aug; 30(6):681-5. PubMed ID: 15256244
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma.
Frasoldati A; Pesenti M; Gallo M; Caroggio A; Salvo D; Valcavi R
Cancer; 2003 Jan; 97(1):90-6. PubMed ID: 12491509
[TBL] [Abstract][Full Text] [Related]
15. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
16. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas.
Lin JD; Huang MJ; Hsu BR; Chao TC; Hsueh C; Liu FH; Liou MJ; Weng HF
J Surg Oncol; 2002 May; 80(1):45-51. PubMed ID: 11967907
[TBL] [Abstract][Full Text] [Related]
17. Surgery of thyroid cancer: twelve years' personal experience.
Pareschi R; Mincione A; Destito D; Mola M; Righini S; Assi A; Dottorini M
Acta Otorhinolaryngol Ital; 2004 Dec; 24(6):348-53. PubMed ID: 15952685
[TBL] [Abstract][Full Text] [Related]
18. [Risk factors of persistent disease at 5 years from diagnosis in differentiated thyroid cancer: study of 63 patients].
Familiar C; Moraga I; Antón T; Gargallo MA; Ramos A; Marco AL; Villa M; Tapia MA
Endocrinol Nutr; 2009; 56(7):361-8. PubMed ID: 19883896
[TBL] [Abstract][Full Text] [Related]
19. Monitoring differentiated thyroid cancer patients with negative serum thyroglobulin. Diagnostic implication of TSH-stimulated antithyroglobulin antibody.
Nam HY; Paeng JC; Chung JK; Kang KW; Cheon GJ; Kim Y; Park DJ; Park YJ; Min HS; Lee DS
Nuklearmedizin; 2014; 53(2):32-8. PubMed ID: 24276613
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution.
Wong R; Topliss DJ; Bach LA; Hamblin PS; Kalff V; Long F; Stockigt JR
Intern Med J; 2009 Mar; 39(3):156-63. PubMed ID: 19383064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
